Galiximab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameGaliximab
Drug Alias Name加利昔单抗galiximabumIDEC-114IDEC-114-20Anti-B7.1-MAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionImmunomodulatorsAnti-CD80
TargetsCluster of differentiation 80
Therapy Area/IndicationsLymphoma, Non-HodgkinLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinLymphoma

Other Information

ATC CodeN/A
Related LinksN/A